Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.

Today, we return to Medexus Pharmaceuticals (MDP.T), a Canadian-based specialty pharma company making waves. We discuss their recent financials, their bargain trading price compared to revenue and the near-term growth potential with the possible addition of treosulfan, a leading-edge stem cell replacement drug.

Enjoy!